Journal articleAm J Clin Oncol2022
The Brown University Oncology Group Experience With FOLFOX + Nab-paclitaxel [FOLFOX-A] for Metastatic and Locally Advanced Pancreatic, BrUOG-292 and BrUOG-318.
- Journal
- Am J Clin Oncol
- Published
- 23 June 2022
- Citations
- 4
- License
- cc by-nc-nd
These are the paper’s bibliographic details. A summary of its population, design, endpoints and findings, each tied to a quote, has not been written for this paper yet.
Ask this document
Answers come only from this document’s own text, as highlighted quotes. If it doesn’t say, you are told so instead of given a guess.
Try
Source text
abstract cc by-nc-nd
Objectives To evaluate response rate, toxicity, and efficacy of the novel combination of nab-paclitaxel, oxaliplatin, 5-fluorouracil, and leucovorin [FOLFOX-A] in patients with advanced pancreatic ductal adenocarcinoma [PDAC]. Methods BrUOG-292 and BrUOG-318 were two concurrently run, prospective, single-arm phase II studies evaluating FOLFOX-A as first-line therapy in patients with metastatic and locally advanced/borderline resectable PDAC respectively. … Excerpt only: this text is the publisher’s. Read it in full at the source.
Trials 1
- Its registry lists this paper as resultsBrUOG 292: FOLFOX-A For Metastatic Pancreatic Cancer: A Phase II Brown University Oncology Research Group Trial NCT02080221↗
The registry lists these as results papers; in a hand check of 27 such links about 78% reported the trial’s results, so read the paper before treating it as the outcome.